Aim: To reveal the exonic and 3’UTR sequences of KRAS, TP53, APC, BRAF, PIK3CA genes in sporadic colorectal tumors and to investigate the clinical relevance of 3’UTR variations in miRNA profiles. Methods: In the study, the exonic and 3’UTR sequences of five genes in 12 sporadic colorectal tumors were extracted by next generation sequencing. In tumors with variation in the 3’UTR region, the changes caused by the variation in the miRNA binding profile were detected. The expression profile of these miRNAs in colorectal and other solid tumors compared to normal tissue was determined. Pathway analysis was performed to determine which signaling pathways miRNAs affect. Results: Case-10 in our study was wild type KRAS and received cetuximab treatment and developed drug resistance. In this case, it was concluded that the expression of KRAS increased and tumorigenesis progressed due to miRNAs that do not bind to this region due to variations in the 3’UTR region. Among these miRNAs, hsa-miR-124-3p was found to have decreased expression in colorectal tumors and to be associated with the ECM-receptor interaction pathway. Conclusion: Variations in the 3’UTR regions of genes critical in the process of carsinogenesis are associated with drug resistance and the process of tumorigenesis.
References
[1]
Dekker, E., Tanis, P.J., Vleugels, J.L.A., et al. (2019) Colorectal Cancer. The Lancet, 394, 1467-1480. https://doi.org/10.1016/S0140-6736(19)32319-0
[2]
Wolpin, B.M. and Mayer, R.J. (2008) Systemic Treatment of Colorectal Cancer. Gastroenterology, 134, 1296-1310. https://doi.org/10.1053/j.gastro.2008.02.098
[3]
Sager, R. (1997) Expression Genetics in Cancer: Shifting the Focus from DNA to RNA. Proceedings of the National Academy of Sciences of the United States of America, 94, 952-955 https://doi.org/10.1073/pnas.94.3.952
[4]
Sepulveda, A.R., Hamilton, S.R., Allegra, C.J., et al. (2017) Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology, 35, 1453-1486. https://doi.org/10.1200/JCO.2016.71.9807
[5]
Taieb, J., Zaanan, A., Le Malicot, K., et al. (2016) Prognostic Effect of BRAF and KRAS Mutations in Patients with Stage III Colon Cancer Treated with Leucovorin, Fluorouracil, and Oxaliplatin with or without Cetuximab. JAMA Oncology, 2, 643-653. https://doi.org/10.1001/jamaoncol.2015.5225
[6]
Tate, J.G., Bamford, S., Jubb, H.C., et al. (2018) COSMIC: The Catalogue of Somatic Mutations in Cancer. Nucleic Acids Research, 47, 941-947. https://doi.org/10.1093/nar/gky1015
[7]
You, J.S. and Jones, P.A. (2012) Cancer Genetics and Epigenetics: Two Sides of the Same Coin? Cancer Cell, 22, 9-20. https://doi.org/10.1016/j.ccr.2012.06.008
[8]
Shen, H. and Laird, P.W. (2013) Interplay between the Cancer Genome and Epigenome. Cell, 153, 38-55. https://doi.org/10.1016/j.cell.2013.03.008
[9]
Ganju, A., Khan, S., Hafeez, B.B., et al. (2017) miRNA Nanotherapeutics for Cancer. Drug Discovery Today, 22, 424-432. https://doi.org/10.1016/j.drudis.2016.10.014
[10]
Qiu, M., Liu, Y., Lin, Q., et al. (2023) A Functional Variant in the RAD51 3’ UTR Is Associated with Survival of Hepatocellular Carcinoma Patients. Gene, 851, Article ID: 146964. https://doi.org/10.1016/j.gene.2022.146964
[11]
Chan, J.J., Tabatabaeian, H. and Tay, Y. (2023) 3’UTR Heterogeneity and Cancer Progression. Trends in Cell Biology, 33, 568-582. https://doi.org/10.1016/j.tcb.2022.10.001
[12]
Yu, Q., Qian, W., Wang, J., et al. (2018) An Indel Polymorphism in the 3’ Untranslated Region of JAK1 Confers Risk for Hepatocellular Carcinoma Possibly by Regulating JAK1 Transcriptional Activity in a Chinese Population. Oncology Letters, 15, 8088-8094. https://doi.org/10.3892/ol.2018.8347
[13]
Chen, Y. and Wang, X. (2019) miRDB: An Online Database for Prediction of Functional microRNA Targets. Nucleic Acids Research, 48, 127-131. https://doi.org/10.1093/nar/gkz757
[14]
Martin, F.J., Amode, M.R., Aneja, A., et al. (2022) Ensembl 2023. Nucleic Acids Research, 51, 933-941. https://doi.org/10.1093/nar/gkac958
[15]
Kodama, Y., Shumway, M. and Leinonen, R. (2011) The Sequence Read Archive: Explosive Growth of Sequencing Data. Nucleic Acids Research, 40, 54-56. https://doi.org/10.1093/nar/gkr854
[16]
Chu, A., Robertson, G., Brooks, D., et al. (2015) Large-Scale Profiling of microRNAs for the Cancer Genome Atlas. Nucleic Acids Research, 44, e3. https://doi.org/10.1093/nar/gkv808
[17]
Vlachos, I.S., Zagganas, K., Paraskevopoulou, M.D., et al. (2015) DIANA-miRPath v3.0: Deciphering microRNA Function with Experimental Support. Nucleic Acids Research, 43, 460-466. https://doi.org/10.1093/nar/gkv403
[18]
Chin, L.J., Ratner, E., Leng, S., et al. (2008) A SNP in a Let-7 microRNA Complementary Site in the KRAS 3’ Untranslated Region Increases Non-Small Cell Lung Cancer Risk. Cancer Research, 68, 8535-8540. https://doi.org/10.1158/0008-5472.CAN-08-2129
[19]
Kim, M. and Slack, F.J. (2014) MicroRNA-Mediated Regulation of KRAS in Cancer. Journal of Hematology & Oncology, 7, Article No. 84. https://doi.org/10.1186/s13045-014-0084-2
[20]
Kataoka, K., Shiraishi, Y., Takeda, Y., et al. (2016) Aberrant PD-L1 Expression through 3’-UTR Disruption in Multiple Cancers. Nature, 534, 402-406. https://doi.org/10.1038/nature18294
[21]
Smits, K.M., Paranjape, T., Nallur, S., et al. (2011) A Let-7 MicroRNA SNP in the KRAS 3’UTR Is Prognostic in Early-Stage Colorectal Cancer. Clinical Cancer Research, 17, 7723-7731. https://doi.org/10.1158/1078-0432.CCR-11-0990
[22]
Marinovic, S., Skrtic, A., Catela Ivkovic, T., et al. (2021) Regulation of KRAS Protein Expression by miR-544a and KRAS-LCS6 Polymorphism in Wild-Type KRAS Sporadic Colon Adenocarcinoma. Human Cell, 34, 1455-1465. https://doi.org/10.1007/s13577-021-00576-2
[23]
Reynolds, N.A. and Wagstaff, A.J. (2004) Cetuximab: In the Treatment of Metastatic Colorectal Cancer. Drugs, 64, 109-118. https://doi.org/10.2165/00003495-200464010-00007
[24]
Valtorta, E., Misale, S., Sartore-Bianchi, A., et al. (2013) KRAS Gene Amplification in Colorectal Cancer and Impact on Response to EGFR-Targeted Therapy. International Journal of Cancer, 133, 1259-1265. https://doi.org/10.1002/ijc.28106
[25]
Misale, S., Yaeger, R., Hobor, S., et al. (2012) Emergence of KRAS Mutations and Acquired Resistance to Anti-EGFR Therapy in Colorectal Cancer. Nature, 486, 532-536. https://doi.org/10.1038/nature11156
[26]
Salmón, M., Alvarez-Díaz, R., Fustero-Torre, C., et al. (2023) Kras Oncogene Ablation Prevents Resistance in Advanced Lung Adenocarcinomas. Journal of Clinical Investigation, 133, e164413. https://doi.org/10.1172/JCI164413
[27]
Lagos-Quintana, M., Rauhut, R., Yalcin, A., et al. (2002) Identification of Tissue-Specific MicroRNAs from Mouse. Current Biology, 12, 735-739. https://doi.org/10.1016/S0960-9822(02)00809-6
[28]
Wang, P., Chen, L., Zhang, J., et al. (2013) Methylation-Mediated Silencing of the miR-124 Genes Facilitates Pancreatic Cancer Progression and Metastasis by Targeting Rac1. Oncogene, 33, 514-524. https://doi.org/10.1038/onc.2012.598
[29]
Shi, X.B., Xue, L., Ma, A.H., et al. (2012) Tumor Suppressive miR-124 Targets Androgen Receptor and Inhibits Proliferation of Prostate Cancer Cells. Oncogene, 32, 4130-4138. https://doi.org/10.1038/onc.2012.425
Zhang, F.J., Cao, W.J., Chang, F.F., et al. (2020) MiR-124-3p Enhances the Sansitivity of Chronic Myelogenous Leukemia Cell K562-R to Imatinib by Targeting ABCA2. Journal of Experimental Hematology, 28, 789-796.
[32]
Wang, Z., Dai, J., Yan, J., et al. (2019) Targeting EZH2 as a Novel Therapeutic Strategy for Sorafenib-Resistant Thyroid Carcinoma. Journal of Cellular and Molecular Medicine, 23, 4770-4778. https://doi.org/10.1111/jcmm.14365
[33]
Shahmohamadnejad, S., Nouri Ghonbalani, Z., Tahbazlahafi, B., et al. (2022) Aberrant Methylation of miR-124 Upregulates DNMT3B in Colorectal Cancer to Accelerate Invasion and Migration. Archives of Physiology and Biochemistry, 128, 1503-1509. https://doi.org/10.1080/13813455.2020.1779311
[34]
Zhang, Y., Zheng, L., Huang, J., et al. (2014) MiR-124 Radiosensitizes Human Colorectal Cancer Cells by Targeting PRRX1. PLOS ONE, 9, e93917. https://doi.org/10.1371/journal.pone.0093917
